Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

JAMA - Journal of the American Medical Association

Volumn 315, Issue 15, 2016, Pages 1600-1609

  Ribas, Antoni ^a   Hamid, Omid ^b   Daud, Adil ^c   Hodi, F Stephen ^d   Wolchok, Jedd D ^e   Kefford, Richard ^f,g   Joshua, Anthony M ^h   Patnaik, Amita ⁱ   Hwu, Wen Jen ^j   Weber, Jeffrey S ^k   Gangadhar, Tara C ^l   Hersey, Peter ^m   Dronca, Roxana ⁿ   Joseph, Richard W ^o   Zarour, Hassane ^p   Chmielowski, Bartosz ^a   Lawrence, Donald P ^q   Algazi, Alain ^c   Rizvi, Naiyer A ^e   Hoffner, Brianna ^b   Mateus, Christine ^r   Gergich, Kevin ^s   Lindia, Jill A ^s   Giannotti, Maxine ^s   Li, Xiaoyun Nicole ^s   Ebbinghaus, Scot ^s   Kang, S Peter ^s   Robert, Caroline ^r   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MELANOMA INSTITUTE AUSTRALIA   (Australia)

^g MACQUARIE UNIVERSITY   (Australia)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ South Texas Accelerated Research Therapeutics   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ MAYO CLINIC   (United States)

^o MAYO CLINIC   (United States)

^p UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^q MASSACHUSETTS GENERAL HOSPITAL   (United States)

^r INSTITUT GUSTAVE ROUSSY   (France)

^s MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; AUSTRALIA; CANADA; CANCER PATIENT; CANCER SURVIVAL; CHILL; COHORT ANALYSIS; COLITIS; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; FRANCE; HEADACHE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MYALGIA; MYOSITIS; NAUSEA; NEPHRITIS; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; THYROIDITIS; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; UVEITIS; VITILIGO; VOMITING; ALGORITHM; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964341647     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.4059     Document Type: Conference Paper

References (24)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
2. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517-2519.
3. + T cells. Cancer Res. 2004;64(3):1140-1145.
4. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-824.
5. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077): 682-687.
6. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
7. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
8. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
9. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab vs ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
10. Hamid O, Robert C, Ribas A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). J Clin Oncol. 2014;32(15)(suppl):Abstract 3000.
11. Robert C, Joshua AM, Weber JS, et al. Pembrolizumab (MK-3475) for advanced melanoma: randomized comparison of two dosing schedules. Poster presented at: European Society for Medical Oncology 2014 Congress; September 28-30, 2014; Madrid, Spain. Abstract LBA34.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
13. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
14. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.3. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed February 23, 2016.
15. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404-413. doi:10.1093/biomet/26.4.404.
16. Garon EB, Rizvi NA, Hui R; et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
17. Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
18. Joseph RW, Elassaiss-Schaap J, Wolchock JD, et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1monoclonal antibodyMK-3475. J Clin Oncol. 2014;32(15)(suppl):Abstract 3015.
19. Ascierto PA, Simeone E, Grimaldi AM, et al. Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med. 2013;11:61.
20. Ascierto PA, Grimaldi AM, Acquavella N, et al. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013;11:137.
21. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695-1701.
22. Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
23. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10): 1020-1030.
24. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.NEngl J Med. 2015;373(1):23-34.